(Q38412031)

English

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.

scientific article published on 05 May 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

phase III clinical trial

0 references

Jean-Marie Boher

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

A Gonçalves

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

J-Y Pierga

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

J-M Ferrero

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M-A Mouret-Reynier

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

T Bachelot

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

R Delva

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M Fabbro

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

F Lerebours

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

J-P Lotz

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

C Linassier

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

N Dohollou

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

J-C Eymard

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

B Leduc

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

J Lemonnier

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

A-L Martin

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

H Roché

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

5 May 2015

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

26

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1692-1697

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Sample Sizes Based on the Log-Rank Statistic in Complex Clinical Trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV216

21 January 2018

Identifiers

10.1093/ANNONC/MDV216

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

release_pruagvpfyfhbhbegfhusxzw6py

1 reference

https://api.fatcat.wiki/v0/release/pruagvpfyfhbhbegfhusxzw6py

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25943350%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38412031&oldid=1836548676"